William Blair Issues Negative Outlook for LRMR Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Stock analysts at William Blair reduced their Q1 2025 earnings per share (EPS) estimates for shares of Larimar Therapeutics in a report issued on Monday, March 24th. William Blair analyst M. Minter now forecasts that the company will earn ($0.46) per share for the quarter, down from their prior forecast of ($0.35). The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. William Blair also issued estimates for Larimar Therapeutics’ Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.01) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.52) EPS and FY2026 earnings at ($2.07) EPS.

A number of other brokerages have also commented on LRMR. HC Wainwright lifted their price target on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday. Guggenheim reaffirmed a “buy” rating and set a $26.00 target price on shares of Larimar Therapeutics in a research report on Tuesday. Truist Financial assumed coverage on Larimar Therapeutics in a research report on Wednesday, January 29th. They issued a “buy” rating and a $18.00 price target on the stock. Finally, Robert W. Baird lowered their price objective on Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating for the company in a research report on Tuesday. Eleven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Larimar Therapeutics has a consensus rating of “Buy” and an average target price of $20.22.

Larimar Therapeutics Price Performance

LRMR opened at $2.38 on Thursday. Larimar Therapeutics has a fifty-two week low of $2.19 and a fifty-two week high of $11.20. The company’s 50 day moving average price is $3.10 and its two-hundred day moving average price is $5.16. The firm has a market capitalization of $151.54 million, a price-to-earnings ratio of -2.07 and a beta of 0.99.

Larimar Therapeutics (NASDAQ:LRMR) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.16).

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in LRMR. Janus Henderson Group PLC grew its stake in Larimar Therapeutics by 15.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,443,286 shares of the company’s stock worth $24,936,000 after purchasing an additional 876,431 shares during the period. Blue Owl Capital Holdings LP boosted its holdings in shares of Larimar Therapeutics by 11.7% during the 4th quarter. Blue Owl Capital Holdings LP now owns 4,653,040 shares of the company’s stock worth $18,007,000 after buying an additional 486,211 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its position in shares of Larimar Therapeutics by 23.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company’s stock worth $8,127,000 after buying an additional 399,123 shares during the period. Alyeska Investment Group L.P. grew its position in shares of Larimar Therapeutics by 38.6% during the 4th quarter. Alyeska Investment Group L.P. now owns 984,077 shares of the company’s stock worth $3,808,000 after buying an additional 273,920 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of Larimar Therapeutics by 45.1% in the 4th quarter. Renaissance Technologies LLC now owns 513,542 shares of the company’s stock valued at $1,987,000 after acquiring an additional 159,700 shares in the last quarter. 91.92% of the stock is owned by institutional investors and hedge funds.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.